Moderna, Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher

AI-generated analysis

📈 Moderna shares climbed 6% to $154, extending a 137% one-month run fueled by Phase 2b melanoma data showing a 49% reduction in recurrence risk.

🔬 The intismeran vaccine program with partner Merck spans nine trials across melanoma, lung, bladder, and renal cell carcinoma indications.

📅 Management is highly confident an interim analysis from the Phase 3 adjuvant melanoma trial will be released in the second half of 2026.

💰 The company guided to up to 10% revenue growth for 2026 and year-end cash reserves between $4.7 billion and $5.2 billion.

🧬 CEO Stéphane Bancel identified oncology as a key focus for the second half of 2026, shifting weight away from the base vaccine franchise.

⚖️ Peer BioNTech edged up only 1%, suggesting the market is backing Moderna's specific asset rather than the broader mRNA cancer category.

📉 The stock has priced a broad franchise off one indication, creating elevated give-back risk if future datasets land short of expectations.

🗓️ The next major public data window is expected at the oncology congress in Madrid in late October 2026.

Bullish Signals
  • Moderna stock surged 6% to $154, extending a 137% one-month rally driven by Phase 2b melanoma data showing a 49% reduction in recurrence risk.
  • The intismeran vaccine with partner Merck has demonstrated efficacy across multiple tumor types, spanning nine Phase 2/3 trials including lung and bladder cancer.
  • Management is highly confident that an interim analysis from the Phase 3 adjuvant melanoma trial will be conducted in the second half of 2026.
  • The company guided to up to 10% revenue growth for 2026 and expects year-end cash reserves between $4.7 billion and $5.2 billion.
Risk Factors
  • The stock has more than doubled in a month, pricing in a broad franchise based on a single indication which creates elevated give-back risk.
  • Investors face the risk that read-across of melanoma success to other tumor types like lung and bladder cancer remains unproven and must be earned.
Full Analysis
Moderna (MRNA) shares surged approximately 6% to $154 in morning trading on Thursday, extending a remarkable 137% gain over the past month. This rally occurred without any new trial results or analyst upgrades, driven primarily by the market's continued digestion of late-stage adjuvant melanoma data presented at ASCO 2026. The specific asset driving this momentum is intismeran, an individualized neoantigen vaccine developed in partnership with Merck (MRK), which demonstrated a 49% reduction in the risk of recurrence or death compared to KEYTRUDA alone. The company has guided for up to 10% revenue growth in 2026 and expects year-end cash reserves between $4.7 billion and $5.2 billion, providing ample funding for its pipeline. Management, including CEO Stéphane Bancel and Chief Development Officer David Berman, maintains high confidence that an interim analysis from the Phase 3 adjuvant melanoma trial will be conducted in the second half of 2026. This upcoming data point is viewed as the critical swing factor for the stock's next leg of performance. Market dynamics suggest investors are pricing in Moderna's specific oncology asset rather than a broad mRNA platform play, evidenced by BioNTech (BNTX) rising only 1% despite its own cancer vaccine program. The bull case relies on the potential read-across of the melanoma success to other tumor types like lung and bladder cancer, though this remains unproven. Conversely, the stock carries elevated give-back risk if future datasets fail to meet the high expectations built during the recent rally.